3 min read

UBC Appoints Bekki Brown President & Chief Executive Officer

Effective January 1, 2023, Bekki Brown, COO of UBC, will be elevated to the role of President & Chief Executive Officer of UBC.
Effective January 1, 2023, Bekki Brown, COO of UBC, will be elevated to the role of President & Chief Executive Officer of UBC.

BLUE BELL, P.A., November 10, 2022 – UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced today that effective January 1, 2023, Bekki Brown, UBC’s Chief Operating Officer, will be elevated to the role of President & Chief Executive Officer.

Bekki’s more than 20 years of senior management experience focused on strategic growth and operational excellence for industry-leading organizations such as Quintiles, INC Research, and Syneos Health, will play an integral role in designing UBC’s long-term market position, expanding their service model, and maintaining their financial strength.

“As we enter the post-COVID world of drug development, we embark on one of the most innovative markets in recent history,” said Patrick Lindsay, President & Chief Executive Officer, UBC. “To best maximize our opportunities, we are now positioning UBC for significant growth, both organically and inorganically. I have the utmost confidence that Bekki will provide the vision, leadership, and management necessary to ensure UBC remains a standard bearer for innovation, quality, and safety in the life sciences industry as we continue to adapt, evolve, and grow.”

In the new year, Mr. Lindsay will join the UBC Board of Directors serving as strategic advisor to the CEO, and the organization, in achieving purposeful growth with a keen focus on identifying inorganic opportunities that support the strategic direction of UBC.

About UBC

United BioSource LLC (UBC) is a leader in the biopharmaceutical market that provides integrated clinical, safety, and commercialization services. UBC brings together renowned scientific research and operations experts with innovative technologies, allowing for the best patient and healthcare provider experience. Comprehensive, end-to-end services cover product and patient population characterization during development and market entry, as well as a focus on the patient experience, safety, and adherence. For additional information, visit www.ubc.com.

Media Inquiries

Amber Frasketi

UBC

Phone: 215.588.8423

Email: amber.frasketi@ubc.com

Other Recent Posts

Press
4 min read

UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025

UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.
Press
5 min read

UBC Announces Partnership with Osmind to Advance the Future of Mental Health Treatment and Research within REMS

First-of-its-kind partnership in mental health care reduces REMS implementation burden, improves the quality of REMS data, and optimizes safe medication use and health outcomes
Press
5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.